Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.01, Zacks reports.
Nautilus Biotechnology Stock Up 2.1 %
Shares of Nautilus Biotechnology stock traded up $0.01 during mid-day trading on Tuesday, reaching $0.69. 74,553 shares of the stock traded hands, compared to its average volume of 108,783. Nautilus Biotechnology has a fifty-two week low of $0.66 and a fifty-two week high of $3.09. The stock has a market capitalization of $87.55 million, a PE ratio of -1.24 and a beta of 1.39. The business has a 50-day moving average of $0.98 and a 200 day moving average of $1.72.
Insiders Place Their Bets
In other Nautilus Biotechnology news, CEO Sujal M. Patel bought 53,300 shares of Nautilus Biotechnology stock in a transaction dated Wednesday, March 19th. The stock was acquired at an average cost of $0.99 per share, with a total value of $52,767.00. Following the completion of the acquisition, the chief executive officer now owns 10,117,788 shares of the company's stock, valued at approximately $10,016,610.12. This represents a 0.53 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 40.50% of the stock is owned by insiders.
Institutional Trading of Nautilus Biotechnology
A hedge fund recently raised its stake in Nautilus Biotechnology stock. Bank of America Corp DE lifted its stake in Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Free Report) by 37.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 49,419 shares of the company's stock after acquiring an additional 13,363 shares during the period. Bank of America Corp DE's holdings in Nautilus Biotechnology were worth $83,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 50.71% of the company's stock.
Wall Street Analysts Forecast Growth
Separately, Guggenheim set a $2.50 target price on shares of Nautilus Biotechnology in a research note on Friday, February 28th.
Check Out Our Latest Stock Report on Nautilus Biotechnology
Nautilus Biotechnology Company Profile
(
Get Free Report)
Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Nautilus Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nautilus Biotechnology wasn't on the list.
While Nautilus Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
